<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://vigi-eye.com/analysis/2026-11-16-ftc-s-bid-to-block-covetrus-mwi-puts-veterinary-distribution-and-pv-information</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FTC&#x27;s bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-16-vercise-dbs-instruction-recall-why-ifu-corrections-matter-to-trial-teams</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Vercise DBS instruction recall: why IFU corrections matter to trial teams</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-16-denmark-s-voltabak-shortage-to-mid-may-2027-shows-how-fragile-single-source-supp</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Denmark&#x27;s Voltabak shortage to mid-May 2027 shows how fragile single-source supply is</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-16-illinois-medicaid-charges-show-no-pharma-link-but-the-compliance-signal-is-worth</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Illinois Medicaid charges show no pharma link, but the compliance signal is worth reading</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-16-chmp-backs-krka-s-generic-of-jakavi-across-three-indications-ec-decision-now-pen</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>CHMP backs Krka&#x27;s generic of Jakavi across three indications; EC decision now pending</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-16-medline-s-bed-recall-remedy-plan-shows-how-device-harm-data-becomes-continued-us</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Medline&#x27;s bed recall remedy plan shows how device harm data becomes continued-use guidance</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-view-paid-is-not-covered-build-the-access-case-around-the-policy-not-the-claims</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Paid is not covered: build the access case around the policy, not the claims</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-ema-consults-on-medically-important-veddra-terms-to-anchor-veterinary-signal-man</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>EMA consults on medically important VeDDRA terms to anchor veterinary signal management</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-tuhura-s-aml-ind-clearance-tests-how-small-biotechs-fund-early-phase-oncology-tr</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>TuHURA&#x27;s AML IND clearance tests how small biotechs fund early-phase oncology trials</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-mhra-s-monthly-licence-list-is-a-cheap-supply-chain-check-as-danish-shortages-mo</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>MHRA&#x27;s monthly licence list is a cheap supply-chain check as Danish shortages mount</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-medicare-fraud-plea-shows-how-kickbacks-and-weak-oversight-corrupt-lab-and-devic</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Medicare fraud plea shows how kickbacks and weak oversight corrupt lab and device supply chains</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-chmp-backs-fortvita-s-pd-1-antibody-zybrivo-in-first-line-non-squamous-nsclc</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>CHMP backs Fortvita&#x27;s PD-1 antibody Zybrivo in first-line non-squamous NSCLC</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-15-ema-drafts-new-list-of-medically-important-veddra-terms-for-veterinary-pharmacov</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>EMA drafts new list of medically important VeDDRA terms for veterinary pharmacovigilance</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-14-ema-s-veterinary-signal-page-phenobarbital-dog-labelling-new-mah-templates-veddr</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14</news:publication_date><news:title>EMA&#x27;s veterinary signal page: phenobarbital dog labelling, new MAH templates, VeDDRA list</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-14-bluejay-finishes-symon-ii-enrolment-but-cash-runway-ends-as-its-510-k-window-clo</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14</news:publication_date><news:title>Bluejay finishes SYMON-II enrolment, but cash runway ends as its 510(k) window closes</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-14-medicare-pays-1-938-01-per-esoguard-test-as-pavmed-s-veris-nears-its-510-k</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14</news:publication_date><news:title>Medicare pays $1,938.01 per EsoGuard test as PAVmed&#x27;s Veris nears its 510(k)</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-14-eu-device-study-pilot-gets-positive-feedback-but-dg-sante-s-webinar-leaves-key-d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14</news:publication_date><news:title>EU device-study pilot gets positive feedback, but DG SANTE&#x27;s webinar leaves key data unpublished</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-14-qezzaqar-withdrawal-what-a-pulled-eu-sarcoma-filing-after-a-negative-chmp-opinio</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14</news:publication_date><news:title>Qezzaqar withdrawal: what a pulled EU sarcoma filing after a negative CHMP opinion means</news:title></news:news></url><url><loc>https://vigi-eye.com/analysis/2026-11-14-prac-publishes-final-phenobarbital-translations-as-eu-veterinary-signal-rules-ti</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14</news:publication_date><news:title>PRAC publishes final phenobarbital translations as EU veterinary signal rules tighten</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/c4335d3357529cd998b2</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/8e1ef866157e4d64419d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/39802c7e0d2a1e04ad6b</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/b3f5093f0e4e19dbb854</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>TOYO Co. reports lower Q3 revenue and net income, but higher nine-month sales</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/a40b6de6d2f75587dbd0</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>China adds Ascentage&#x27;s lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/fa8c3ac9a2b6fa191f4d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/555ee69281fde4a165b5</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/896143e696a7d3b61f65</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>CG Oncology&#x27;s cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/759e2c19c46c004273a7</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/3d80ac99c12131c4d99e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Aptevo&#x27;s mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/e1a7043792a701c5a0ab</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/ac14460b3841b93308c3</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>ALX Oncology reports $147.2M cash, with ALX2004 Phase 1 data due in December</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/3e1965c18b8cf9e18b90</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/53a027eb2276493c3d35</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/830553fe8d6f853a8df8</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Radiopharm&#x27;s 18F-RAD101 PET shows 93.5% MRI agreement in interim Phase 2b brain metastasis data</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/8622c4b06cbe662ece51</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Eloxx doses first Alport patients in Phase 2b and wins FDA IND clearance in ADPKD</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/d6b2bcb7cdc0f522ab31</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>CG Oncology deck details cretostimogene bladder cancer data, FDA designations and manufacturing scale-up</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/a0ab78ecfe0b8616e274</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Apnimed&#x27;s sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/31a7944e7b80697816f1</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>XORTX completes clinical supply manufacturing for XORLO oxypurinol gout trial XRX-OXY-102</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/f2e6f35a760d227636ad</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Adagio Medical&#x27;s VT ablation PMA remains under FDA review as board explores strategic alternatives</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/70d1d627479ef29d54ae</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA sets 25 March 2027 goal date for Unicycive&#x27;s resubmitted oxylanthanum carbonate application</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/18fcea9b95431e229d06</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA grants orphan drug designation to Noema&#x27;s basimglurant for trigeminal neuralgia</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/28104071906c1b31c2c3</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Sono Group updates share counts ahead of 11 December redomiciliation vote</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/5e21f9715c9570f09ec0</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Mentari Therapeutics reports $63.0M nine-month net loss, backed by related-party note</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/317c9442f6cc06467a3d</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA issues complete response letter for Summit&#x27;s ivonescimab in EGFR-mutant NSCLC</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/3320c2b155512e929bee</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>InMed completes Mentari merger and renames itself Mentari Therapeutics, with PACAP migraine antibody in Phase 1</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/8b73c0c156ec433818a5</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Organigram receives Nasdaq minimum bid price deficiency notice, with compliance deadline of May 2027</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/5763a977ec1a306cd110</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>USFDA closes Dr. Reddy&#x27;s Bachupally FTO-3 inspection with Voluntary Action Indicated status</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/58a70c0bbf85e9ddd3f8</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Moleculin completes dosing of 90 patients in Part A of pivotal AML trial MIRACLE</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/252a06ad73146d6de457</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Lexeo reports interim LX2020 data in PKP2 cardiomyopathy, cites FDA openness to NSVT endpoint</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/7c5a01f92e4a0e6fc87c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Lexeo starts pivotal SUNRISE-FA 2 trial of LX2006 in Friedreich ataxia cardiomyopathy</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/3a57035b46fd334e8e81</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/cb8c25fc3420ea7560ea</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Cypherpunk reports $306M Q3 net income as Leap starts sirexatamab partnering process</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/18a0abcdd866a61aa390</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Aclaris begins Phase 2b trial of modzatinib in lichen planus</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/b87fcd77b4ff4f9f34a3</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>MapLight starts set-up of confirmatory Phase 3 ZEPHYR-2 in schizophrenia</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/d2ddd81d8adb383515d5</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Helus Pharma&#x27;s HLP003 meets primary endpoint in Phase 3 APPROACH depression trial</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/a32bdd9c8ed0a48ab01a</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Larimar completes BLA submission for nomlabofusp in Friedreich&#x27;s ataxia, seeking accelerated approval</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/f13a139da8a9977aef27</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Helus Pharma completes enrolment in Phase 3 APPROACH depression trial; topline still due Q4 2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/6788ab9f6b20f30edd42</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>XORTX Therapeutics warns of going-concern doubt as cash falls to $318,846</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/df0c0858b31b28208671</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>CorMedix posts $54.5M Q3 revenue, narrows 2026 EBITDA guidance and details Heron asset deal</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/a78d592e98f944dfda33</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Rejuvenate Biomed completes last patient visit in Phase 2 MINT-COPD trial of RJx-01</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/19eaa448c8f3b8a83c79</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/e662d52bb7a8c08dac7c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA approves Roche&#x27;s Gazyva for primary membranous nephropathy, a first for the condition</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/c/f5cc98f29ab8cd58b7c6</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Lakefront Biotherapeutics launches second €50m share buyback after completing first programme</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/1c9f43bae27830bd</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Commission grants marketing authorisation for Revolution Medicines&#x27; daraxonrasib product Rasonque</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/e7f9ae40d55d18d3</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>INFARMED updates Portugal&#x27;s reference price groups for fourth quarter of 2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/73347b3fa7e7a9d0</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>BfArM lists urgent field safety notice for ICU Medical&#x27;s TEGO hemodialysis connector</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/9583be39e8e12285</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Florida man pleads guilty to $42M Medicare fraud involving DME and cancer genetic tests</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/02f0b26f5f681b6c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Pleasanton drug discovery firm Cyion to pay $528,336 over alleged False Claims Act grant violations</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2ab43265ee4dddfe</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>AIFA updates Italy&#x27;s Transparency Lists of generics and reference prices as of 16 November</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/778eb21b9317e67a</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>AEMPS issues guidance on correct use of biocides in Spanish healthcare facilities</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/9386266501989fe8</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>ANSM issues new accreditation rules for external quality control bodies, repealing 2019 order</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/6b129e61005b4195</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>AIFA publishes updated transparency lists with generic reference prices as of 16 November</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/bc9e14e5fc6c4e3c</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Real4Reg final symposium at Infarmed showcases real-world data studies and free training</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/54ba5b33094ba7b6</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>MSD to end Emend (aprepitant) marketing in EU/EEA; Italy&#x27;s 125 mg + 80 mg capsules go from 30 November</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/2f60206fdc1a3a52</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Baltic paper-free leaflet project to continue after 2026 with Commission&#x27;s backing</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/59b4fc7fc08cf90b</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Estonia&#x27;s human medicines market grows 11.7% in third quarter of 2026</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/d06bddb1a78f48a2</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Denmark flags supply problems for Fresenius Kabi ceftazidime 1000 mg injection powder</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/4e3609d524f20202</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Denmark flags supply problems for Fresenius Kabi ceftazidime 2000 mg injection</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/e4efe7462e799be5</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>EMA recommends Gazyvaro for adults with active systemic lupus erythematosus, SÚKL reports</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/0d596f196048f95b</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>MHRA Strategy 2030 sets mission of health and prosperity through scientific excellence</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/a409c1691d07e20e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>AIFA: Emend 125 mg + 80 mg capsules to leave Italian market on 30 November</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/46d2a0c6a41b430b</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Dutch inspectorate publishes report on July 2026 inspection of Theranostics Erasmus MC BV</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/3496d8b2bf96e063</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Greek regulator EOF orders market recall of non-sterile zig-zag cotton gauze roll</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/c3d7cfde76680f19</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>AEMPS begins therapeutic positioning reports for products backed by October CHMP opinions</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/d27def5894dd5d29</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Spain&#x27;s major-impact medicine supply problems drop below 0.20% for first time in five years</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/0245bcaeec70fe3e</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>MHRA publishes Women&#x27;s Health Programme for 2026-2030 to strengthen evidence and regulation</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/6362cec82593c3e8</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>MHRA launches Women&#x27;s Health Programme to close evidence gaps on medicines and devices</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/8ff064c9bdd4e4e3</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Etac Clean 60 cm shower chair: castor wheel may detach on units with raised-seat kit</news:title></news:news></url><url><loc>https://vigi-eye.com/news/item/u/b3072e7beea3a3d4</loc><news:news><news:publication><news:name>VigiEye</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Etac issues field safety notice for Swift Mobil 2 range via Dutch inspectorate</news:title></news:news></url></urlset>